ORIENTBIO Inc.: debt-to-equity, ROE and more
KOSPI, Legal name ORIENTBIO Inc.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 18.0%
- Equity ratio
- 84.7%
- ROE
- -18.4%
- Op. margin
- -10.5%
- Rev. growth
- 5.0%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 2 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 47.3% | 67.9% | -32.2% | 3.6% | n/a |
| FY2022 separate | 26.2% | 79.3% | 41.1% | -14.4% | -49.5% |
| FY2023 separate | 13.5% | 88.1% | -17.4% | 5.0% | 9.7% |
| FY2024 separate | 14.0% | 87.7% | 15.1% | -2.3% | -2.8% |
| FY2025 separate | 18.0% | 84.7% | -18.4% | -10.5% | 5.0% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩52.0B | ₩26.3B | ₩28.8B | ₩28.0B | ₩29.4B |
| Operating profit | ₩1.9B | -₩3.8B | ₩1.5B | -₩645.9M | -₩3.1B |
| Pre-tax income | -₩15.7B | -₩3.4B | -₩12.6B | ₩12.9B | -₩13.2B |
| Net income | -₩15.6B | ₩34.2B | -₩12.4B | ₩12.9B | -₩13.2B |
| Total assets | ₩71.5B | ₩105.0B | ₩81.1B | ₩97.0B | ₩84.8B |
| Total liabilities | ₩23.0B | ₩21.8B | ₩9.7B | ₩11.9B | ₩12.9B |
| Total equity | ₩48.5B | ₩83.2B | ₩71.4B | ₩85.1B | ₩71.8B |
| Paid-in capital | ₩59.3B | 0 | 0 | ₩59.3B | ₩59.3B |
| Debt/equity (source value) | 47.3% | 26.2% | 13.5% | 14.0% | 18.0% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Mar
- Founded
- 1959-04-16
- Listed
- 76/12/28
- Employees
- 123
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110030116
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 오리엔트바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.